(Q43763813)

English

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis (English)

1 reference

Europe PubMed Central

26 November 2017

multiple sclerosis

0 references

0 references

author name string

van Boxel-Dezaire AH

1

1 reference

Europe PubMed Central

26 November 2017

Hoff SC

2

1 reference

Europe PubMed Central

26 November 2017

van Oosten BW

3

1 reference

Europe PubMed Central

26 November 2017

Verweij CL

4

1 reference

Europe PubMed Central

26 November 2017

Dräger AM

5

1 reference

Europe PubMed Central

26 November 2017

Adèr HJ

6

1 reference

Europe PubMed Central

26 November 2017

van Houwelingen JC

7

1 reference

Europe PubMed Central

26 November 2017

Barkhof F

8

1 reference

Europe PubMed Central

26 November 2017

Polman CH

9

1 reference

Europe PubMed Central

26 November 2017

Nagelkerken L

10

1 reference

Europe PubMed Central

26 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 June 1999

1 reference

Europe PubMed Central

26 November 2017

Annals of Neurology

1 reference

Europe PubMed Central

26 November 2017

45

1 reference

Europe PubMed Central

26 November 2017

695-703

1 reference

Europe PubMed Central

26 November 2017

6

1 reference

Europe PubMed Central

26 November 2017

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease.

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1002%2F1531-8249%28199906%2945%3A6%3C695%3A%3AAID-ANA3%3E3.0.CO%3B2-R

21 January 2018

Identifiers

10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43763813&oldid=2103131121"